Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer' returned 226 results - Page 1 of 12  FEATURED RESULTS Cancer Diagnostic Testing World Markets Drug Delivery in Cancer - Technologies, Markets and Companies Antibody Drug Target Atlas in Oncology Pharmacogenetics of Breast Cancer: Towards the Individualiza... Cancer and its Management, 6th Edition   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Non-small Cell Lung Cancer Drug Market in South Korea   Frost & Sullivan, Aug 2011, Pages: 81 This research service presents an overview and analysis of the non-small cell lung cancer drug market in South Korea from 2010 to 2017. It provides an analysis of the patient load, typical treatment Salient Review Non-Small Cell Lung Cancer: Advances in Blood Biomarkers, 2011   BioPharm Reports (VennBio Ltd.), Oct 2011, Pages: 60 This Salient Review presents the findings of more than 150 clinical studies or commercial disclosures relating to non-small cell lung cancer biomarkers, in the blood. These findings, which were Lung Cancer and Non-Small Cell Lung Cancer Therapy Area Pipeline Report   Life Science Analytics, March 2011, Pages: 1729 Lung Cancer and Non-Small Cell Lung Cancer Therapy Area Pipeline Report contains detailed information on the lung cancer and non-small cell lung cancer drug pipeline. This report provides insight Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017   GlobalData, Dec 2010, Pages: 64 Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018   GlobalData, Nov 2011, Pages: 138 Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Non-Small Targeted Therapeutics in Non-Small Cell Lung Cancer   Bioseeker, April 2007, Pages: 282 lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin Epidemiology: Non-Small Cell Lung Cancer - Despite global efforts to stop smoking, incidence rates will remain unchanged   Datamonitor, Nov 2011, Pages: 48 10-year epidemiology forecast of non-small cell lung cancer. - Understand the key epidemiologic risk factors associated with non-small cell lung cancer. Highlights - Most people are not diagnosed Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter   Espicom Business Intelligence Ltd, March 2009, Pages: 206 A comprehensive examination of the non-small cell lung cancer market and therapeutic approaches Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report   Life Science Analytics, March 2009, Pages: 831 Life Science Analytics, Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report contains detailed information on the non-small-cell lung cancer or lung Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2012   GlobalData, Jan 2012, Pages: 167 Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H2, 2011" provides data Non-Small Cell Lung Cancer Global Clinical Trials Review, Q4, 2010   GlobalData, Dec 2010, Pages: 114 Non-Small Cell Lung Cancer Global Clinical Trials Review, Q4, 2010 Summary Our clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, Q4, 2010"” provides data on the Non Non-Small Cell Lung Cancer - Pipeline Review, H2 2011   Global Markets Direct, Sep 2011, Pages: 605 Non-Small Cell Lung Cancer - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Non-Small Cell Lung Cancer - Pipeline Review, H2 2011', provides an overview of the Non-Small Cell Lung Non-Small Cell Lung Cancer - Pipeline Review, Q1 2011   Global Markets Direct, Feb 2011, Pages: 538 Non-Small Cell Lung Cancer - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Non-Small Cell Lung Cancer - Pipeline Review, Q1 2011', provides an overview of the Non-Small Cell Lung Non-Small Cell Lung Cancer - Pipeline Review, Q4 2010   Global Markets Direct, Dec 2010, Pages: 495 Non-Small Cell Lung Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Non-Small Cell Lung Cancer Pipeline Review, Q4 2010”, provides an overview of the Non-Small Cell Lung Cancer The 2011 Report on Non-Small Cell Lung Cancer Therapeutics: World Market Segmentation by City   ICON Group International, Jan 2011, Pages: 329 Market Potential Estimation Methodology Overview This study covers the world outlook for non-small cell lung cancer therapeutics across more than 2000 cities. For the year reported, estimates The 2011-2016 World Outlook for Non-Small Cell Lung Cancer Therapeutics   ICON Group International, Jan 2011, Pages: 197 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for non-small cell lung cancer therapeutics is not actual The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Greater China   ICON Group International, Jan 2011, Pages: 142 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for non-small cell lung cancer therapeutics in Greater The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in India   ICON Group International, Jan 2011, Pages: 319 than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for non-small cell lung cancer therapeutics in India The 2011-2016 Outlook for Non-Small Cell Lung Cancer Therapeutics in Japan   ICON Group International, Jan 2011, Pages: 141 than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for non-small cell lung cancer therapeutics in Japan Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements   Datamonitor, April 2008, Pages: 266 Introduction Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical markets Results:  First -   Prev -   1 -   2 -   3 -   4 -   5 -   6 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network